retatrutide clinical trials phase 2 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Phase 2 Trial of Retatrutide

Raghav K, Kopetz S , Yuan Y

You can have adequate hormone levels but poor signaling if receptor expression is low or receptor sensitivity is impaired

Most research focused on short-to-medium term use (days to weeks)

Compared to conventional radiotherapy, stereotactic radiotherapy appears to have lower complication rates ( 6.8 Surgery Surgical treatment in PRLomas is typically considered only in rare cases of DAs resistance or extremely poor tolerance

To the possible persistence of the initial pathogen that triggered the PAIS, one should add the reactivation of latent viruses such as EBV, HHV-6 or VZV (8285), all frequently observed in PAIS, possibly as a result of a reduced efficiency of their control by the immune system

The peptide PT-141 is a derivative of melanotan II